MoonLake's sonelokimab met all key PsA endpoints in Phase 3 trial.
MoonLake Immunotherapeutics reported positive results from its Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis, alongside cash runway projections to mid-2028, reflecting potential for a leading treatment in another multi-billion dollar market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day